Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study

Tristan Robert-Van Houtteghem, Marguerite Fournier, Fabrice Jardin et al. Nov 03, 2025 pp. 4495-4495 10.1182/blood-2025-4495

Abstract Introduction. A growing body of evidence from both solid and hematologic malignancies has demonstrated a significant center effect...

Icans mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol – a pilot study

Gil Fridberg, Odelia Amit, Yehonatan Sherf et al. Nov 03, 2025 pp. 1943-1943 10.1182/blood-2025-1943

Abstract Background CAR-T therapy has transformed the treatment of relapsed or refractory LBCL, with CD28-based products offering rapid resp...

Evolution of care and outcomes of kidney transplantation in plasma cell dyscrasias: A single center experience

Gaddiel Ahmed-Robles, Krishna Allam, Rasha El-Rifai et al. Nov 03, 2025 pp. 6377-6377 10.1182/blood-2025-6377

Abstract Background: Historically, managing kidney failure from Plasma Cell Dyscrasias (PCDs) was limited to dialysis, as kidney transplanta...

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Elias Jabbour, Timothy Hughes, Richard Van Etten et al. Nov 03, 2025 pp. 901-901 10.1182/blood-2025-901

Abstract Introduction: While outcomes for patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) have substantially improved wi...

Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium

Eli Zolotov, Noa Biran, Patrick Roney et al. Nov 03, 2025 pp. 5852-5852 10.1182/blood-2025-5852

Abstract Introduction: The CAR-T therapies ide-cel and cilta-cel are approved for patients (pts) with relapsed/refractory multiple myeloma (...

Unraveling the mysteries of platelet fatigue in cold storage: Calcium release dynamics and energy metabolism as therapeutic targets.

Lusha Xiang, Michael Meledeo Nov 03, 2025 pp. 3146-3146 10.1182/blood-2025-3146

Abstract Background: Cold storage improves platelet shelf-life due in part to suppressed metabolism, but platelet function still rapidly dec...

The dysregulated lipid metabolism is associated with CD8+ T cell senescence in HIV-associated diffuse large B cell lymphoma

Qing Xiao, Yifeng Tang, Jun Li et al. Nov 03, 2025 pp. 3000-3000 10.1182/blood-2025-3000

Abstract Backgrounds Our previous study revealed that HIV+ DLBCL patients exhibit senescent-like dysfunction in CD8+ T cells. While it is kn...

Targeting immunoproteasome-dependent β-catenin degradation as a therapeutic strategy in Relapsed/Refractory acute lymphoblastic leukemia

Jodi Forward, Kadriye Nehir Cosgun, Tianhao Yin et al. Nov 03, 2025 pp. 5092-5092 10.1182/blood-2025-5092

Abstract Background and Significance: As central component of canonical WNT-signaling, β-catenin functions as oncogenic driver that promotes...

Impact of treatment facility type on survival outcomes in mantle cell lymphoma: A 20-year NCDB analysis

Eleftheria Atalla, Ysaith Orellana Ascencio, Carolina Velez-Mejia et al. Nov 03, 2025 pp. 3572-3572 10.1182/blood-2025-3572

Abstract Background: Mantle Cell Lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma characterized by hetero...

Global, regional, and national burden of G6PD deficiency: A three-decade analysis across 204 countries

Daaniya Tariq, Muzamil Khan, Ummul Asfeen et al. Nov 03, 2025 pp. 6435-6435 10.1182/blood-2025-6435

Abstract Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common enzymatic disorders g...

Hemoglobin S beta thalessemia plus: Clinical analysis from the Georgia comprehensive sickle cell center at grady memorial hospital, Atlanta, Georgia.

Abraham Attah, Dhikshitha Balaji, Maureen Njoku et al. Nov 03, 2025 pp. 411-411 10.1182/blood-2025-411

Abstract Introduction: Hemoglobin (Hb) S beta thalassemia plus (β+) is a variant of sickle cell disease (SCD) characterized by inheritance o...

Targeting SP1 condensates suppresses HNRNPUL1 via super-enhancers to attenuate Acute Myeloid Leukemia progression

Yuchen Wen, Chun Chen, Chi Kong LI et al. Nov 03, 2025 pp. 3267-3267 10.1182/blood-2025-3267

Abstract Acute myeloid leukemia (AML) is a genetically heterogeneous myeloid malignancy that accounts for approximately 20% of pediatric leu...

Real-world chronic lymphocytic leukemia/small lymphocytic lymphoma treatment patterns at Florida cancer specialists & research institute among patients receiving zanubrutinib immediately following prior BTKi therapy

Amanda Warner, Xiaoliang Wang, Ashley Hernandez et al. Nov 03, 2025 pp. 8062-8062 10.1182/blood-2025-8062

Abstract Introduction Zanubrutinib, a second-generation Bruton tyrosine kinase inhibitor (BTKi), is approved for the treatment of previously...

Use of emapalumab is associated with rapid and sustained benefits in primary HLH subgroups, including CNS involvement and previously untreated patients: Pooled analysis of prospective trials NI-0501-04, NI-0501-05 and NI-0501-09

Franco Locatelli, Michael Jordan, Didier Halimi et al. Nov 03, 2025 pp. 2979-2979 10.1182/blood-2025-2979

Abstract Introduction: To provide additional insights into treatment with emapalumab in primary hemophagocytic lymphohistiocytosis (pHLH), w...

Chronic pulmonary LPS exposure in cystic fibrosis drives maladaptive pro-inflammatory hematopoietic stem and progenitor cells

Rubia Isler Mancuso, Evrett Thompson, Cassia Lisboa Braga et al. Nov 03, 2025 pp. 3175-3175 10.1182/blood-2025-3175

Abstract Background: Persistent lung inflammation characterizes cystic fibrosis (CF), mainly driven by myeloid cells (neutrophils and monocyt...

Second primary malignancies in multiple myeloma: Incidence, survival and prognostic factors from a large single-center observational study

Noriko Nishimura, Andriy Derkach, Kelly Barnett et al. Nov 03, 2025 pp. 2213-2213 10.1182/blood-2025-2213

Abstract Introduction: The risk of second primary malignancies (SPMs) has emerged as a growing clinical concern in patients with multiple my...

Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study

Xiaojing Yan, Jingchen Sui Nov 03, 2025 pp. 7204-7204 10.1182/blood-2025-7204

Abstract Background: Glofitamab has demonstrated promising efficacy in relapsed/refractory (R/R) Diffuse large B-cell lymphoma (DLBCL) in gl...

Single-cell multiomics reveals molecular identities and clonal dynamics of MRD progression in Myelodysplastic Syndromes after stem cell transplant

Yu-Hsiang Chen, Timothy Bi, Minhang Xu et al. Nov 03, 2025 pp. 674-674 10.1182/blood-2025-674

Abstract Background: Stem cell transplantation (SCT) is the only curative option for higher-risk myelodysplastic syndromes (MDS). Neverthele...

Molecular and cytogenetic landscape of black patients with myelodysplastic syndrome in the veterans health affairs

Veronica Guerra, Meagan Jacoby, Martin Schoen Nov 03, 2025 pp. 2078-2078 10.1182/blood-2025-2078

Abstract Introduction: Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytope...

Development and clinical evaluation of a cost-effective method with capillary electrophoresis sequencer-based fragment analysis assay panel for genetic classification and risk stratification in de novo AML

Mayu Ikeda, Hikaru Hattori, Yuki Namba et al. Nov 03, 2025 pp. 7854-7854 10.1182/blood-2025-7854

Abstract Background In patients diagnosed with AML, the implementation of leukemia gene testing in accordance with the ELN 2022 guidelines i...

Anakinra for hemophagocytic lymphohistiocytosis: A real-world, multicenter retrospective study on efficacy, safety, and response durability

Lin Wu, Jingshi Wang, Na Wei et al. Nov 03, 2025 pp. 6573-6573 10.1182/blood-2025-6573

Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome of excessive inflammation driven by immune dysr...

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

Linda Fabris, Warren Fiskus, Kavi O'Connor et al. Nov 03, 2025 pp. 3759-3759 10.1182/blood-2025-3759

Abstract Background: Bromodomain and Extra-Terminal (BET) motif inhibitor therapy, alone or in combination with JAK inhibition (JAKi), is eme...

Gene therapy in three classical hematological disorders – is social media making a difference?

Anika Khera, Rajiv Pruthi, Ronald Go et al. Nov 03, 2025 pp. 7844-7844 10.1182/blood-2025-7844

Abstract Gentically driven classical hematological disorders have variable prevelance in the general population, sickle cell disease (SCD) b...

Genomic characteristics of diffuse large B-cell lymphoma associated with Wiskott-Aldrich syndrome

Asami Kodera, Tomohiro Nakano, Hidehiro Minegishi et al. Nov 03, 2025 pp. 5317-5317 10.1182/blood-2025-5317

Abstract Introduction Wiskott-Aldrich syndrome (WAS) is a rare X-linked inborn error of immunity (IEI) characterized by thrombocytopenia, ec...

Geriatric hematologic care in Latin America: Results from a regional survey of hematology centers

Héctor Alejandro Vaquera Alfaro, Alia Guadalupe Ordoñez Ayala, Carlos Emir Córdova-Lucio et al. Nov 03, 2025 pp. 4417-4417 10.1182/blood-2025-4417

Abstract Background Older adults with cancer often face additional challenges in disease management. Limited awareness among medical profess...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page